LHC Group (NASDAQ:LHCG)‘s stock had its “buy” rating restated by analysts at Oppenheimer in a note issued to investors on Thursday. They currently have a $85.00 price target on the health services provider’s stock. Oppenheimer’s price objective suggests a potential upside of 33.02% from the company’s previous close.

A number of other equities research analysts have also recently weighed in on the stock. Royal Bank Of Canada reiterated a “buy” rating and set a $70.00 price target on shares of LHC Group in a research report on Wednesday, September 6th. Bank of America initiated coverage on shares of LHC Group in a research report on Monday, August 21st. They set a “buy” rating and a $76.00 price target for the company. BidaskClub upgraded shares of LHC Group from a “hold” rating to a “buy” rating in a research report on Friday, August 18th. Zacks Investment Research upgraded shares of LHC Group from a “hold” rating to a “buy” rating and set a $79.00 price target for the company in a research report on Wednesday, November 8th. Finally, Craig Hallum reiterated a “buy” rating and set a $80.00 price target (up from $67.00) on shares of LHC Group in a research report on Tuesday, November 7th. Three equities research analysts have rated the stock with a hold rating and ten have assigned a buy rating to the stock. The company presently has a consensus rating of “Buy” and an average price target of $77.10.

Shares of LHC Group (LHCG) traded up $0.94 during mid-day trading on Thursday, reaching $63.90. 278,800 shares of the company’s stock were exchanged, compared to its average volume of 148,111. The company has a quick ratio of 1.77, a current ratio of 1.77 and a debt-to-equity ratio of 0.24. LHC Group has a one year low of $41.66 and a one year high of $76.14. The stock has a market capitalization of $1,150.85, a P/E ratio of 27.02, a PEG ratio of 1.87 and a beta of 0.69.

LHC Group (NASDAQ:LHCG) last issued its earnings results on Monday, November 6th. The health services provider reported $0.64 EPS for the quarter, topping analysts’ consensus estimates of $0.60 by $0.04. LHC Group had a net margin of 4.09% and a return on equity of 9.52%. The company had revenue of $272.90 million for the quarter, compared to the consensus estimate of $265.35 million. During the same period in the previous year, the firm earned $0.54 earnings per share. LHC Group’s quarterly revenue was up 18.2% compared to the same quarter last year. analysts anticipate that LHC Group will post 2.4 earnings per share for the current fiscal year.

In related news, COO Donald Dwayne Stelly sold 2,650 shares of LHC Group stock in a transaction that occurred on Friday, September 8th. The shares were sold at an average price of $65.34, for a total value of $173,151.00. Following the completion of the transaction, the chief operating officer now owns 109,235 shares in the company, valued at $7,137,414.90. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Insiders own 14.80% of the company’s stock.

A number of institutional investors have recently modified their holdings of the stock. Schwab Charles Investment Management Inc. lifted its position in shares of LHC Group by 7.0% during the 1st quarter. Schwab Charles Investment Management Inc. now owns 84,338 shares of the health services provider’s stock worth $4,546,000 after buying an additional 5,551 shares during the last quarter. Bank of America Corp DE lifted its position in shares of LHC Group by 123.5% during the 1st quarter. Bank of America Corp DE now owns 34,658 shares of the health services provider’s stock worth $1,868,000 after buying an additional 19,154 shares during the last quarter. State Street Corp lifted its position in shares of LHC Group by 4.7% during the 1st quarter. State Street Corp now owns 391,375 shares of the health services provider’s stock worth $21,095,000 after buying an additional 17,439 shares during the last quarter. Capstone Asset Management Co. purchased a new stake in shares of LHC Group during the 2nd quarter worth approximately $245,000. Finally, Aperio Group LLC lifted its position in shares of LHC Group by 8.6% during the 2nd quarter. Aperio Group LLC now owns 6,932 shares of the health services provider’s stock worth $471,000 after buying an additional 549 shares during the last quarter. Institutional investors own 85.51% of the company’s stock.

WARNING: “LHC Group’s (LHCG) “Buy” Rating Reaffirmed at Oppenheimer” was originally published by American Banking News and is owned by of American Banking News. If you are viewing this article on another domain, it was illegally copied and republished in violation of U.S. and international trademark and copyright law. The legal version of this article can be viewed at https://www.americanbankingnews.com/2017/12/07/lhc-groups-lhcg-buy-rating-reaffirmed-at-oppenheimer.html.

LHC Group Company Profile

LHC Group, Inc is a holding company. The Company provides post-acute healthcare services to patients through its home nursing agencies, hospice agencies, community-based services agencies and long-term acute care hospitals (LTACHs). The Company operates through four segments: home health services, hospice services, community-based services and facility-based services.

Analyst Recommendations for LHC Group (NASDAQ:LHCG)

Receive News & Ratings for LHC Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LHC Group and related companies with MarketBeat.com's FREE daily email newsletter.